Beyond the Signs ​and Symptoms: ​The Developmental Burden of AD in Children

• Explore the disease burden and potential life-long impact in children with uncontrolled AD
• Investigate the importance of targeting type 2 inflammation in AD, with a focus on skin barrier normalization and implications for disease course modification
• Review emerging clinical and real-world data supporting early intervention in reducing the potential life-long impact of AD

Atopic dermatitis imposes significant burden on pediatric patients, spurring research for innovative therapies in the evolving treatment landscape. In this ADVENT-sponsored symposium at the ESPD 2023 Congress in Spain, experts Michael J. Cork, MD, PhD (University of Sheffield, UK), Pablo Coto Segura, MD, PhD (Hospital Vital Alvarez-Buylla de Mieres, Spain), and Michele Ramien, MD (University of Calgary, Canada), discussed the burden of atopic dermatitis on children and their caregivers, reviewed the importance of targeting type 2 inflammation with a particular focus on skin barrier normalization, and delved into the implications of the emerging systemic treatment landscape for practicing dermatologists.